

**Egypt Hyperlipidemia Drugs Market, By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, Competition, Forecast, & Opportunities, 2028**

Market Report (3 business days) | 2023-09-11 | 90 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

**Report description:**

Egypt hyperlipidemia drugs market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include increase in the prevalence of the condition, rising awareness of the health risks associated with hyperlipidemia, government initiatives to improve healthcare infrastructure, increase in disposable income, and the introduction of innovative drugs.

Hyperlipidemia, a medical condition characterized by elevated levels of cholesterol and triglycerides in the blood, is a significant health concern in Egypt. The condition affects millions of Egyptians and is a major risk factor for cardiovascular diseases. The primary factor fueling the growth of the hyperlipidemia drugs market in Egypt is the increase in the prevalence of the hyperlipidemia. A sedentary lifestyle, unhealthy diet, and genetic factors are among the major contributors to the rising incidence of hyperlipidemia in Egypt.

The awareness of the health risks associated with hyperlipidemia has been steadily increasing among the population in Egypt. This has led to an increased demand for hyperlipidemia drugs, as more people seek medical intervention to manage their condition. The growing awareness of the health risks associated with hyperlipidemia has also led to an increase in the number of screening programs and campaigns aimed at early detection of the condition.

The Egyptian government has been investing heavily in the healthcare sector in recent years, with a particular focus on improving the infrastructure and facilities available for medical care. This has led to an increase in the availability of hyperlipidemia drugs, as well as improved access to medical care for those who need it.

The field of medicine has seen significant technological advancements in recent years, and the hyperlipidemia drugs market in Egypt has not been left behind. The development of new technologies has led to the creation of innovative drugs and treatments,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

which have improved the management and treatment of hyperlipidemia. The introduction of innovative hyperlipidemia drugs in the market has also contributed to the growth of the market. New drugs that are more effective in controlling cholesterol levels and have fewer side effects have been introduced in recent years, leading to an increased demand for these drugs. Gene therapy, nanotechnology, artificial intelligence, wearable technology, and telemedicine are just some of the advancements that have improved the management and treatment of hyperlipidemia.

The increased demand for personalized medicine, growing interest in natural and alternative therapies, increased focus on preventative care, growing aging population, and technological advancements are expected to influence the growth of the market.

There is a growing focus on prevention of hyperlipidemia and its associated health risks in Egypt. This is leading to an increased emphasis on lifestyle modifications, including changes to diet and exercise, as well as the use of preventive medication such as statins. This increased focus on prevention is expected to support the growth of the hyperlipidemia drugs market in the forecast period.

Pharmaceutical companies are investing in advancements in drug delivery technologies, which is expected to drive the growth of the Egypt hyperlipidemia drugs market. For example, newer drug delivery systems can improve the bioavailability of the drug and reduce side effects, making them more effective and tolerable for patients.

The increasing investment in healthcare infrastructure in Egypt is expected to support the growth of the hyperlipidemia drugs market. This includes investments in healthcare facilities, medical technology, and healthcare personnel. As a result, patients are likely to have better access to medical treatment, including hyperlipidemia drugs, which will drive the growth of the market. The increasing use of digital health technology, including telemedicine and mobile health applications, is also supporting the growth of the Egypt hyperlipidemia drugs market. These technologies are making it easier for patients to access medical care and manage their health conditions, including hyperlipidemia. For example, patients can use mobile health applications to track their lipid levels and receive personalized advice on diet and lifestyle modifications, which can help reduce their risk of cardiovascular events.

To meet the growing demand for hyperlipidemia drugs, pharmaceutical companies are investing in research and development to develop new and more effective treatments. This is expected to result in the launch of new hyperlipidemia drugs in the coming years, further driving market growth.

However, there are several challenges that are hampering the growth of the market in the forecast period. These challenges include limited access to healthcare services, high cost of drugs, lack of patient awareness, limited availability of generic drugs, and regulatory challenges. The high cost of hyperlipidemia drugs is a significant challenge for the growth of the market in Egypt. Many patients in the country cannot afford the high cost of these drugs, which can limit their access to treatment. This is especially true for patients who do not have health insurance coverage or who have limited financial resources.

The limited availability of generic hyperlipidemia drugs is also a challenge for the growth of the market in Egypt. Generic drugs are often more affordable than branded drugs and can increase access to treatment for patients. However, there are few generic hyperlipidemia drugs available in the market, which can limit their availability and affordability for patients.

**Rising Awareness Regarding the Risks of Cardiovascular Disease (CVD) Brought on by Prolonged Hypercholesterolemia**

Rising awareness regarding the risks of cardiovascular disease (CVD) brought on by prolonged hypercholesterolemia is expected to have a significant impact on the growth of the Egypt hyperlipidemia drugs market in the coming years. The rising prevalence of CVD in Egypt has led to a growing awareness of the importance of controlling hyperlipidemia to prevent the development of CVD. This increased awareness is expected to drive the demand for hyperlipidemia drugs in the coming years.

The main driver of this increased awareness is the growing availability of information on the risks of hyperlipidemia and CVD through various channels, including media campaigns, patient education programs, and healthcare provider training. This increased awareness has led to a greater understanding of the importance of controlling hyperlipidemia to reduce the risk of CVD and has resulted in more patients seeking medical treatment for the condition.

Moreover, healthcare providers are increasingly focusing on prevention and early detection of hyperlipidemia and its associated health risks, including CVD. This has led to more frequent lipid level screening for patients, and early intervention to prevent the development of CVD. In addition, the adoption of guidelines for the management of hyperlipidemia by healthcare providers is also supporting the growth of the hyperlipidemia drugs market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Growing Prevalence of Hyperlipidemia

The growing prevalence of hyperlipidemia is expected to have a significant impact on the growth of the Egypt hyperlipidemia drugs market in the coming years. Hyperlipidemia is a medical condition characterized by high levels of lipids (fats) in the blood, including cholesterol and triglycerides, and is a major risk factor for cardiovascular disease (CVD) such as heart attack and strokes.

Egypt is facing a significant burden of hyperlipidemia, with a high prevalence of the condition among its population. The increasing prevalence of hyperlipidemia in Egypt is attributed to several factors, including changing dietary patterns, sedentary lifestyles, and increasing rates of obesity and diabetes.

As the prevalence of hyperlipidemia continues to rise in Egypt, the demand for hyperlipidemia drugs is expected to increase as well. This is because hyperlipidemia is a chronic condition that requires ongoing management, and patients may require long-term treatment with hyperlipidemia drugs to control their lipid levels and reduce their risk of developing CVD.

Furthermore, as the population ages and life expectancy increases, the incidence of hyperlipidemia is also expected to increase, further driving demand for hyperlipidemia drugs. In addition, the increasing availability and affordability of hyperlipidemia drugs in Egypt is also expected to support market growth.

## Market Segmentation

The Egypt hyperlipidemia drugs market can be segmented by drug class, distribution channel, and region. By drug class, the market can be segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, combination, and others. Based on distribution channel, the market is further segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

## Market Players

Amoun Pharmaceutical Company, Pharco Corporation, EIPICO (Egyptian International Pharmaceutical Industries Company), Rameda Pharmaceuticals, Minapharm Pharmaceuticals, Delta Pharma, Memphis For Pharmaceutical & Chemical Industries, and Biopharm Group Egypt are among others some of the leading companies operating in the market.

## Report Scope:

In this report, Egypt hyperlipidemia drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

### □□Egypt Hyperlipidemia Drugs Market, By Drug Class

- o□Statins
- o□Bile Acid Sequestrants
- o□Cholesterol Absorption Inhibitors
- o□PCSK9 Inhibitors
- o□Combination
- o□Others

### □□Egypt Hyperlipidemia Drugs Market, By Distribution Channel

- o□Hospital Pharmacy
- o□Retail Pharmacy
- o□Online Pharmacy

### □□Egypt Hyperlipidemia Drugs Market, By Region

- o□Cairo
- o□Qalyubia
- o□Alexandria
- o□Port Said
- o□Giza
- o□Suez
- o□Rest of Egypt

## Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Egypt hyperlipidemia drugs market has been provided.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□ Detailed analysis and profiling of additional market players (up to five).

## Table of Contents:

1. □ Product Overview
  - 1.1. □ Market Definition
  - 1.2. □ Scope of the Market
    - 1.2.1. □ Markets Covered
    - 1.2.2. □ Years Considered for Study
    - 1.2.3. □ Key Market Segmentations
2. □ Research Methodology
  - 2.1. □ Objective of the Study
  - 2.2. □ Baseline Methodology
  - 2.3. □ Key Industry Partners
  - 2.4. □ Major Association and Secondary Types
  - 2.5. □ Forecasting Methodology
  - 2.6. □ Data Triangulation & Validation
  - 2.7. □ Assumptions and Limitations
3. □ Executive Summary
  - 3.1. □ Overview of the Market
  - 3.2. □ Overview of Key Market Segmentations
  - 3.3. □ Overview of Key Market Players
  - 3.4. □ Overview of Key Regions/Countries
  - 3.5. □ Overview of Market Drivers, Challenges, and Trends
4. □ Voice of Customer
5. □ Egypt hyperlipidemia drugs market Outlook
  - 5.1. □ Market Size & Forecast
    - 5.1.1. □ By Value
  - 5.2. □ Market Share & Forecast
    - 5.2.1. □ By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, Others)
    - 5.2.2. □ By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    - 5.2.3. □ By Region (Cairo, Qalyubia, Alexandria, Port Said, Giza, Suez)
    - 5.2.4. □ By Company (2022)
  - 5.3. □ Product Market Map
6. □ Cairo hyperlipidemia drugs market Outlook
  - 6.1. □ Market Size & Forecast
    - 6.1.1. □ By Value
  - 6.2. □ Market Share & Forecast
    - 6.2.1. □ By Drug Class
7. □ Qalyubia hyperlipidemia drugs market Outlook
  - 7.1. □ Market Size & Forecast
    - 7.1.1. □ By Value
  - 7.2. □ Market Share & Forecast
    - 7.2.1. □ By Drug Class

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8. Alexandria hyperlipidemia drugs market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Drug Class
- 9. Port Said hyperlipidemia drugs market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value
  - 9.2. Market Share & Forecast
    - 9.2.1. By Drug Class
- 10. Giza hyperlipidemia drugs market Outlook
  - 10.1. Market Size & Forecast
    - 10.1.1. By Value
  - 10.2. Market Share & Forecast
    - 10.2.1. By Drug Class
- 11. Suez hyperlipidemia drugs market Outlook
  - 11.1. Market Size & Forecast
    - 11.1.1. By Value
  - 11.2. Market Share & Forecast
    - 11.2.1. By Drug Class
- 12. Market Dynamics
  - 12.1. Drivers
  - 12.2. Challenges
- 13. Market Trends & Developments
  - 13.1. Merger & Acquisition
  - 13.2. Product Development
  - 13.3. Recent Developments
- 14. Policy & Regulatory Landscape
- 15. Egypt Economic Profile
- 16. Competitive Landscape
  - 16.1. Business Overview
  - 16.2. Company Snapshot
  - 16.3. Products & Services
  - 16.4. Financials (As Reported)
  - 16.5. Recent Developments
    - 16.5.1. Amoun Pharmaceutical Company
    - 16.5.2. Pharco Corporation
    - 16.5.3. EIPICO (Egyptian International Pharmaceutical Industries Company)
    - 16.5.4. Rameda Pharmaceuticals
    - 16.5.5. Minapharm Pharmaceuticals
    - 16.5.6. Delta Pharma
    - 16.5.7. Memphis For Pharmaceutical & Chemical Industries
    - 16.5.8. Biopharm Group
- 17. Strategic Recommendations
- 18. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Egypt Hyperlipidemia Drugs Market, By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, Competition, Forecast, & Opportunities, 2028**

Market Report (3 business days) | 2023-09-11 | 90 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-09

Signature

A large, empty rectangular box intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)